ENDOVASC--------PATENTZULASSUNG n° 2 - 500 Beiträge pro Seite

[js200]

Und wieder 50% heute, merkt das denn keiner ????

Strong buy

JS200

[js200]

Heute wieder 59 %

Ja wenn keiner will!!! auch gut

War nur eine info von meiner Seite, ich habe 127% in 2 Tagen

JS200

[Tittenpaula]

bitte wkn ansagen

danke TP

[Ichweissauchnicht]

Hallo, js200
von welcher Aktie redest Du hier ?
Nenne doch mal Aktienkürzel, WKN usw...
ichweissauchnicht....

[Tittenpaula]

ah er meint ENDV , ist ein penny in USA

[desastermaster]

Hallo,
in der Tat hat sich die Aktie (OTCBB ENDV) in den letzten fuenf Handelstagen unter hohen Umsaetzen vervierfacht.
Am 8. Nov. gab es gute Nachrichten zur Vereinfachung des Protokolls der Phase III Studie von Liprostin und das Einverstaendnis der FDA zun Ueberspringen von Phase I/II fuer NRA. Sie koennten damit im Sommer 2002 zwei Phase III studien am laufen haben. Siehe news at www.endovasc.com
Am 15. Nov. haben sie einen Bescheid des US-Patentamtes bezueglich ihrer biodegradable stents erhalten.
Auesserst mau ist - soweit ich das ueberblicke - die aktuelle Finanzlage. Schulden, negatives Eigenkapital, hohe burnrate. Sie brauchen dringend frische Kohle.
Vielleicht kommt die ja bald...
ansonsten kann ich mir den momentanen hype naemlich
nicht erklaeren.
Best
dm
PS: In Berlin (919591) exisiert praktisch kein Umsatz

[Tittenpaula]

times and sales bitte mal dazu anschauen, die von wo: machen sich wohl hier einen spass !!

[js200]

Hier ein paar Infos

BusinessWire, 11/15/2001 07:32

Endovasc Announces U.S. Patent Office Notification for Resorbable Biodegradable Stent

MONTGOMERY, Texas--(BW HealthWire)--Nov. 15, 2001--Endovasc Ltd. Inc. announced today the U.S. Patent Office (USPTO) has sent the company notification of allowable claims on the company`s continuation-in-part of its previous stent patent, U.S. Patent 5,980,551 issued Nov. 9, 1999 for a Totally Resorbable Biodegradable Stent

"This second patent greatly strengthens our Company`s intellectual property built around this technology," said the inventor and CEO of Endovasc, Dr. David P. Summers. "We have three prior stent patents which mention, either in text or in claims, a biodegradable stent with the earliest citation going back to a 1992 filing date."

The Company`s resorbable prosthesis (stent) is a unique concept in the medical device market. There are no stent products currently on the market which will totally degrade by natural biological processes leaving the vessel or organ totally free from any prosthetic remains. The resorbable prosthesis maintains strength needed to acutely open and maintain a vessel, duct, tract or organ confirmation and also precise chronicity controlling the release and delivery of drugs or biologic agents providing a medicinal therapy.

The multi-billion dollar market for medical devices continues to grow, with the top three medical device manufacturers reporting worldwide stent sales during 2000 at over a billion dollars.

About Endovasc Ltd. Inc.

Endovasc Ltd. Inc. is a biopharmaceutical biotech company pioneering drug delivery technology. The Company`s products and processes, which include Liprostin(TM) (liposome encapsulated PGE-1), NRA (Nicotine Receptor Agonist, an angiogenic agent), PROSTENT(TM) stent-coating technology, and a biodegradable resorbable prosthesis are covered by patents, license and trade secrets for competing in a multi-billion dollar market.

The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc Ltd. Inc., contact:

CONTACT: Endovasc Ltd. Inc., Montgomery

New Business Development and Investor Relations:

John (Jack) T. Sorbi, 936/448-2222

Fax: [phone]

[e-mail]

BusinessWire, 11/08/2001 16:26

FDA Recommends Endovasc Revise Phase III Plans for NRA and Simplify Liprostin Phase III Trial; Study Revisions Could Mean a Solid Future for the Company

MONTGOMERY, Texas--(BW HealthWire)--Nov. 8, 2001--Endovasc Ltd. Inc. (OTCBB:ENDV)(Berlin:ED7) today announced very encouraging results of meetings with the Food and Drug Administration (FDA) regarding Liprostin(TM) and Nicotine Receptor Agonist (NRA). FDA agreed to the company`s simplifying Liprostin(TM)`s Phase III protocol for the treatment of critical limb ischemia (CLI) and to proceed from NRA animal studies to Phase III clinical trials for treatment of chronic coronary ischemia which provides the company opportunities to escalate its timeline to market. Based on the results of these meetings, Endovasc is now proceeding with development of Phase III protocol, bypassing Phase I/II for the NRA product and revisions to its Phase III protocol for Liprostin(TM), which includes revised end points and extended patient enrollment.

"We were extremely encouraged by these meetings," stated Dr. David Summers, chairman and CEO. "In light of our FDA meetings, changes to the protocols for both products are being initiated, which means that both Phase III trials could be in full swing during the first quarter, 2002. As we progress, we will keep everyone informed. This is great news to present at our annual meeting on Friday, Nov. 9. We have two potential "home run" products that are now in the final stage of regulatory approval. This is simply remarkable for a small company such as ours."

The company stated that a revised Liprostin(TM) Phase III protocol will be submitted to the FDA by the end of this month, allowing the first patient to be treated sometime in early January 2002.

The company`s other product, NRA-angiogenic agent, intra-coronary injection protocol plan for chronic coronary ischemia, which calls for a single episode of injections into the blood-deficient area of the heart, is designed to stimulate growth of new blood vessels in the heart to relieve intractable anginal pain and improve the patient quality of life. Results from the company`s large animal studies on dogs and pigs indicate that a single series of injections of the nicotine receptor agonist, all done during a single hospital procedure could stimulate a significant growth of new blood vessels. The company expects that this new blood supply will provide relief from chronic chest pain and estimates there are a minimum of 400,000 patients that could benefit from this new procedure. The company will meet with the FDA prior to the formal submission of the new Phase III protocol before the end of the year and anticipates Phase III NRA clinical trials could start in the first quarter of 2002.

About the company:

Endovasc Ltd. Inc. is a biopharmaceutical/biotech company pioneering liposomal drug delivery technology. In addition to Liprostin(TM) and NRA, the company is developing a stent-coating technology that has shown encouraging results in recently concluded pig studies and, a biodegradable, resorbable stent, all covered by patents, licenses and trade secrets for competing in a multi-billion dollar market.

The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc Ltd. Inc., contact:

CONTACT: Endovasc Ltd. Inc., Montgomery

New Business Development and Investor Relations:

John (Jack) T. Sorbi Jr., 936/448-2222


JS200

[e-mail]

[js200]

Hier neue Infos

Wieder 43 %, sieht besser aus als verschiedene andere Aktien, wie CALY usw.

BusinessWire, 11/26/2001 13:53

Endovasc Study Shows Tiny Amounts of Nicotine May Help Patients Grow Their Own Heart Bypasses; Company Confident That New Therapy Will Benefit Thousands of Patients With Heart Disease

MONTGOMERY, Texas--(BW HealthWire)--Nov. 26, 2001--Endovasc Ltd. Inc. (OTCBB:ENDV)(BERLIN:ED7), a biopharmaceutical/biotech company today released new information on the results of its preliminary large animal studies using nicotine receptor agonist (NRA) to treat chronic myocardial ischemia. The studies were performed by Daniel Burkhoff, MD, Ph.D., director of the cardiac physiology laboratory at Columbia University in New York. In the safety study, normal healthy dogs were given 15 intracoronary injections with total doses ranging from 0.1 micrograms/ml up to 10.0 micrograms/ml with all dogs surviving and no unexpected clinical sequelae.

In a subsequent study designed to examine the stimulation of new blood flow in the ischemic heart of Yorkshire miniswine, the effects of single treatment of nicotine using the ameroid constrictor model demonstrated significant evidence of angiogenesis, showing DNA synthesis indicative of dividing endothelial and smooth muscle cells and compensatory vessel collateralization using various staining methods. "These new data are simply striking," said Dr. Burkhoff. "All previous studies included a 21-day regimen of nicotine in drinking water, daily injections, or implantable osmotic pumps. In this study we achieved practically the same effect in the heart with a single treatment! We also saw significant evidence of increase in endocardial flow, both at rest and when the heart was under stress."

The NRA experiments will continue under Dr. Burkhoff at Columbia, and will include NRA coated stents using the company`s proprietary liposomal formulation for a controlled release of NRA. According to the company, much of the work will continue to be sponsored by an outside biomedical research foundation.

The company stated that the evidence of angiogenesis in skeletal muscle in the mouse and rabbit proved that ischemic peripheral limbs could be stimulated to produce new blood flow even when a major artery was completely occluded. "With the additional data presented by Dr. Chris Heeschen last week at the American Heart Association (Heeschen, C. et al., Nicotine Enhances Angiogenesis and Collateral Development in Hind Limb Ischemia; Stanford University and Frankfurt University), wherein the rabbit model of ischemic hind limb demonstrated a phenomenal 33% increase in blood flow compared to the controls, we will likely ask the FDA to extend its approval to an NRA trial for PDA," said Summers. "The obvious take home message is this: NRA does produce safe and effective angiogenesis in both blood-starved skeletal tissues of the limbs and blood-starved heart muscle in the animal kingdom. We are convinced that this effect will carry over to the clinic. With FDA`s approval of our new protocol, we will be ready to treat patients with similar diseases."

About Endovasc Ltd. Inc. Endovasc Ltd. Inc. is a biopharmaceutical/biotech company pioneering liposomal drug delivery technology. The Company`s products and processes, which include Liprostin(TM) (liposome encapsulated PGE-1), NRA (Nicotine Receptor Agonist, angiogenesis agent), stent-coating technology, and a biodegradable/resorbable stent are covered by patents, license and trade secrets for competing in a multi-billion dollar market.

The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc Ltd. Inc., contact:


Meine Empfehlung lautet : STRONG BUY

JS200

[js200]

Hier eine kleine Info

BusinessWire, 12/06/2001 08:33
Endovasc Ltd Inc. Completes FDA Suggested Revisions for Nicotine Receptor Agonist; Company Schedules Pre-IND Meeting and Submission With FDA

MONTGOMERY, Texas--(BW HealthWire)--Dec. 6, 2001--Endovasc Ltd. Inc. (OTCBB:ENDV)(Berlin:ED7) today announces the completion of the FDA suggested Phase III revisions for Nicotine Receptor Agonist and has scheduled the Pre-IND meeting within the month. The final meeting for the IND submission to the agency will be completed by Jan. 31, 2002. "NRA trials for the treatment of chronic myocardia ischemia are scheduled to begin in April 2002", according to Dr. David Summers, chairman and CEO. "With the FDA`s advice and suggestions, we have lowered the study population and have reduced the end points needed to demonstrate significant efficacy."

Dr. David Summers stated, "The rewriting of the NRA protocol has been done in record time and we look forward to positive results from our Pre-IND meeting and subsequent IND submission with the FDA! This exceeds the company`s expectations and could escalate our time to market for this product."

NRA is an angiogenic agent that will target chronic myocardia ischemia. The NRA intra-coronary protocol plan calls for a single episode of NRA injections into blood-deficient (ischemic) areas of the heart. It is designed to stimulate the growth of new blood vessels in the heart to relieve intractable anginal pain and improve the patient`s quality of life. NRA was tested in recently completed animal studies using dogs and pigs and shows that a single series of injections of NRA, all done during a single hospital procedure, could stimulate a significant growth of new blood vessels. "All indications are that this new blood supply will provide relief from chronic chest pain," according to Dr. Summers. "There are an estimated 400,000 patients that can benefit from this procedure each year, and we`re excited to be leading the way in the fight against heart disease."
About Endovasc Ltd. Inc
Endovasc Ltd., Inc. is a biopharmaceutical/biotech company pioneering liposomal drug delivery technology. The Company`s products and processes, which include Liprostin(TM) (liposome encapsulated PGE-1), NRA (Nicotine Receptor Agonist, angiogenesis agent), stent-coating technology and a biodegradable/resorbable stent, are covered by patents, license and trade secrets for competing in a multi-billion dollar market.
The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release.

JS200

[js200]

Rat zum Einkauf bei Interesse:
tätigen bei 0,110 $ bis 0,115 $
Widerstand bei 0,175 $ 200ter Tageslinie
Bleiben immer nach 50%
Viel Glück bei ENDV
Strong buy

JS200

[js200]

Dreieckformation fast fertig, Ausbruch Morgen oder Übermorgen.

Ziel : 0,175$
Heute: 0,125$

STRONG BUY

JS200

[js200]

Vorgestern 0,125 $
Gestern 0,130 $
Heute 0,135 $
Jeden Tag langsam aber stetig nach oben, wer springt mit auf den Zug nach Norden ????

KEINER ???? WIESO ????

JS200

[js200]

HEUTE 0,175 $ ist doch toll

Beim Bruch der 200ter TAGESLINIE Morgen oder ÜBERMORGEN sin 0,250 $ drin.

Zur INFO

Keiner glaubt mir ????
Seht mal meine ersten POSTINGS und berechnet mal die Prozente die Ihr gewonnen hättet.

JS200

[js200]

Heute : 0,2025 $ (+11,11%)

JS200

[js200]

Neue Infos

Endovasc Ltd. Inc. Announces Office Action by U.S. Patent Office On Method of Sterically Stabilized Liposomes
19 Dec 2001, 08:34am ET
E-mail or Print this story
- - - - -
MONTGOMERY, Texas--(BW HealthWire)--Dec. 19, 2001--
Patent Office Determines Claims Drawn To Five Separate and

Distinct Inventions Filed By Dr. David P. Summers

And The Late Dr. Danilo Lasic In June 1999

Endovasc Ltd Inc. (OTCBB:ENDV)(Berlin:ED7) today announced the most recent office action by the U.S. Patent and Trademark Office (USPTO) regarding a patent application by Endovasc scientists for sterically stabilized liposomes for retained drug delivery entitled, "Sterically Stabilized Liposomes With Improvement of Blood Retention Times and Targeting of Sites of Disease by Prostaglandins in Particulate Drug Carriers." The USPTO stated that Endovasc`s new method claims in the pending application were directed to five distinct inventions classified in different classes and subclasses and requested election under 35 U.S.C. 121 of one invention for further prosecution in the pending application.

"The Office Action came as a pleasant surprise," said Company chairman and CEO, Dr. David P. Summers. "Of course, we are delighted to prosecute each invention separately. As in the case of a major discovery, it sometimes leads to the discovery of different methods of use or preparations. In our case, it is a liposomal or collodial moiety, wherein each of the methods have different modes of operation, different functions or different modes of action and effects and is practiced with materially different components and process steps." According to Vice-President of Research and Development, Dr. Diane Dottavio, "Stabilizing liposomes for extended periods of time for retaining drugs in circulation was the direction being taken by Endovasc researchers, Dr. Summers and the late Dr. Danilo Lasic, shortly before his untimely death. Should these discoveries turn into separate patents, they will significantly enhance the Company`s intellectual property and liposome library."

"In the last few weeks of his life, while continuing to work with Endovasc, Dr. Lasic developed plans for approximately 15 new concepts for inventions on liposome drug delivery," said Dr. Summers. "I was privileged to work closely with Dr. Lasic, and because of what we were able to accomplish as a result of his genius, Endovasc and the entire medical community may benefit for years to come."

The Company stated it has elected to prosecute the invention classified in class 424, subclass 496 for a method of sterically stabilizing a liposome for the delivery of PGE-1 and other drugs that avoid uptake by the reticuloendothelial system (RES) from days to weeks and reserved the right to file divisional applications to protect the non-elected inventions. The invention provides for long-term treatment from a single injection for patients suffering from peripheral artery disease (PAD), inflammatory diseases, liver dysfunction and chronic ischemic cerebral vascular diseases.

Endovasc Ltd. Inc. is a biopharmaceutical/biotech company pioneering liposomal drug delivery technology. The Company`s products and processes, including Liprostin(TM) (liposome encapsulated PGE-1), NRA (Nicotine Receptor Agonist, angiogenesis agent), stent-coating technology and a biodegradable/resorbable stent, are covered by patents, license and trade secrets for competing in a multi-billion dollar market.

The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc Ltd. Inc., contact:


CONTACT: Endovasc Ltd. Inc., Montgomery


JS200

[JS222]

@Morchel

Ziehen wir mit bis zur 0,3$ Grenze oder höher, wie ist deine Meinung.

Ich bleibe dabei, wenn man überlegt, dass ENDV schon mal 15$
Wert war, sind 0,3 PINUTS

Ich bin überzeugt von ENDV, habe mir 30.000 Gratisaktien zugelegt innerhalb eines Monats.

Gehts hoch ist Ok
Gehts runter, das bedeutet für mich keinen Verlust.

Strong buy

JS222

[js200]

Endovasc Ltd. Inc. Announces U.S. Patent Office Notice of Allowance for Surface Coating Technology; Endovasc Expands Its Drug Delivery Technology Platform To Five Patents
14 Jan 2002, 08:37am ET
E-mail or Print this story
- - - - -
MONTGOMERY, Texas--(BW HealthWire)--Jan. 14, 2002--Endovasc Ltd., Inc. (OTCBB:ENDV)(Berlin:ED7) announced today that the U.S. Patent and Trademark Office (USPTO) has issued to the Company a Notice of Allowance for its patent application filed on May 1999 covering the use of biodegradable surface coating and method for making same. The technology used in this patent covers Endovasc`s stent-coating process called PROSTENT(TM), which coats vascular stents to prevent restenosis (reblockage) after vascular stenting. Endovasc is a biotechnology company focused in the area of cardiovascular disease, pioneering drug delivery technology designed to deliver and release drugs to their intended targets in an efficient and controlled manner.
Dr. David P. Summers, chairman and CEO of Endovasc, said, "We are very pleased to announce this news today. Not only does it allow us to continue our work in the area of stent coating using our own pipeline of cardiovascular clinical products, but it will assist us as we continue our business development efforts to collaborate with other pharmaceutical companies. One of our goals is to become a leader in the area of drug delivery. With this additional technology, we will now be able to offer to the pharmaceutical industry our research services in the area of surface coating as well as liposomal delivery of small molecules. We believe that a stent coated with a product that safely and effectively lessens the chance for restenosis would be well received by the medical community in the treatment of cardiovascular disease."

The Company is currently conducting preclinical work on stent coating utilizing two of its proprietary clinical products: Liprostin(TM), a liposomal formulation of Prostaglandin E-1 and Nicotine Receptor Agonist, an angiogenic agent.

The multi-billion dollar market for medical devices continues to grow with the top three medical device manufacturers reporting worldwide stent sales during 2000 at over a billion dollars. Stents are commonly deployed after angioplasty in an effort to hold the walls of the affected vessel open. Unfortunately, nearly half of the patients that undergo this procedure must have it repeated in three to six months because of restenosis due to more plaque build up. According to the American Heart Association there are approximately 450,000 angioplasty procedures annually.

Endovasc Ltd. Inc. is a biotechnology focused in the area of cardiovascular disease, pioneering drug delivery technology designed to deliver and release drugs to their intended targets in an efficient and controlled manner. The Company`s products and processes include: Liprostin(TM), Nicotine Receptor Agonist, PROSTENT(TM) stent-coating technology and a biodegradable resorbable prosthesis.

The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release.


JS200

[js200]

BB:ENDV

Steht vor deutlichen KAUFSIGNAL !!! oder ????

JS200

[desastermaster]

Hallo,
Gurkenalarm bei ENDV.
Hier die news:

United States Patent and Trademark Office Grants Endovasc A Notice of Allowance for ANGIOGENIX(TM)
3/21/2002 11:45:00 AM
MONTGOMERY, Texas, Mar 21, 2002 /PRNewswire-FirstCall via COMTEX/ -- Endovasc Ltd., Inc. (ENDV) announced today that the United States Patent and Trademark Office (USPTO) has granted a Notice of Allowance for ANGIOGENIX(TM), new trademark for the Company`s Nicotine Receptor Agonist (NRA) angiogenic product. Endovasc holds the worldwide, exclusive license from Stanford University for their unique discovery of nicotine as an angiogenic (new blood vessel growth) agent.

Dr. David P. Summers, Chairman and CEO stated that, "ANGIOGENIX(TM) gives the Company product identification for NRA as it moves forward to develop, manufacture, use and sell its nicotine and nicotine agonist product for therapeutic angiogenesis. The Company believes ANGIOGENIX(TM) could be an effective tool for a range of diseases and ailments that affect millions of people worldwide. Earlier this year, the Company expanded the potential for NRA by signing an Option Agreement with Stanford for the exclusive, worldwide patent license for the use of nicotine in stem cell and progenitor cell recruitment focused in the areas of cardiology and neurology.

The Company announced in early February the positive results of its Pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA). The IND, to be filed in the first quarter of 2002, will be for Phase III clinical trials to evaluate the safety and efficacy of ANGIOGENIX(TM) as a treatment of chronic myocardial ischemia.

Endovasc Ltd. Inc. is a biotechnology company focused in the area of cardiovascular disease, pioneering drug delivery technology designed to deliver and release drugs to their intended targets in an efficient and controlled manner. In addition to ANGIOGENIX(TM), the Company`s products and processes include: Liprostin(TM), PROSTENT(TM) stent-coating technology, and a biodegradable resorbable prosthesis.

The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc, please visit www.endovasc.com .

SOURCE Endovasc Ltd., Inc.

Copyright (C) 2002 PR Newswire. All rights reserved

[js200]

bb:ENDV

Sie steigt wieder

Kurs 0,085$

JS200

[js200]

Endovasc to Present Canine Results of Intramyocardial Injection of Angiogenix(TM
9 May 2002, 07:02am ET
E-mail or Print this story
- - - - -
/FROM PR NEWSWIRE LOS ANGELES 213-626-5500/ [STK] ENDV [IN] MTC OTC BIO [SU] OTC TO BUSINESS AND MEDICAL EDITORS:

Endovasc to Present Canine Results of Intramyocardial

Injection of Angiogenix(TM)

MONTGOMERY, Texas, May 9 /PRNewswire-FirstCall/ -- Endovasc Ltd., Inc. (BB:ENDV; Berlin: ED7) today announced it will present new data in a poster titled, Nicotine Delivered via Intramyocardial Injections Proved Safe in Canines at the 11th International Congress on Cardiovascular Pharmacotherapy (ISCP) in Montreal, Quebec May 18-21. The poster will present new data on the safety of intramyocardial catheter injections of Angiogenix(TM) in dogs.

The canine trial was carried out at Columbia University`s College of Physicians and Surgeons in New York by Daniel Burkhoff, M.D., Ph.D., Associate Professor of Medicine.

Nine dogs, randomly divided into three groups, received fifteen injections of Angiogenix(TM), the Company`s new angiogenic agent, in the ventricular region of the heart using the MicroHeart (Mountain View, CA) Injection catheter System. Three different levels of the drug were given, ranging from 10-fold below to 10-fold above the therapeutic dose. Left Ventricular (LV) function was assessed by electrocardiogram, comparing baseline to LV function 7 days after treatment.

Dr. Diane Dottavio, Vice President of Research and Development said, "It was a very interesting study. Although all hearts appeared normal upon gross visual inspection, histological analysis revealed evidence of new vascular growth around the injection sites as evidenced by small regions of interstitial fibrosis. There was no evidence of any detectable change in ventricular function either on a global or regional level. Moreover, there were no pathological anomalies or significant changes from baseline in the blood chemistry, hematology and urine analyses, regardless of the dosage." This data demonstrates not only a wider margin of safety and tolerance than previously anticipated, but also shows evidence of the beginning of the angiogenic process in only seven days.

According to the Company, it reviewed this data with FDA in February when Phase III protocols were approved for Angiogenix(TM). The Company plans to release its completed study on The Treatment of Chronic Myocardial Ischemia in Porcine Model with Angiogenix(TM) in October.

Endovasc Ltd. Inc. is a biotechnology company focused in the area of cardiovascular disease, pioneering drug delivery technology designed to deliver and release drugs to their intended targets in an efficient and controlled manner. In addition to Liprostin(TM), the Company`s products and processes include: ANGIOGENIX(TM) (Nicotine Receptor Agonist), PROSTENT(TM) stent-coating technology, and a biodegradable resorbable stent prosthesis.

The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc, please visit www.endovasc.com . (Investor questions and requests for materials can be submitted online.)

MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X36714788 SOURCE Endovasc Ltd. Inc.

-0- 05/09/2002

/CONTACT: Endovasc Ltd., Inc. Investor Relations, [phone], Fax, [phone]/

/Web site: http://www.endovasc.com /


JS200